Sumatriptan Succinate And Naproxen Sodium Tablet
NDC Package 44183-850-09
Package Information
Sumatriptan Succinate And Naproxen Sodium tablets is sumatriptan and Naproxen Sodium Tablets are indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. This formulation utilizes a tablet delivery system. Marketed by Currax Pharmaceuticals Llc Dba Cypress, Hawthorn, Macoven, this product is identified by NDC 44183-850 and is authorized under FDA application NDA021926.
Identification & Billing
- RxCUI: 849450 - SUMAtriptan 85 MG / naproxen sodium 500 MG Oral Tablet
- RxCUI: 849450 - naproxen sodium 500 MG / sumatriptan 85 MG Oral Tablet
- RxCUI: 849450 - naproxen sodium 500 MG / sumatriptan (as sumatriptan succinate) 85 MG Oral Tablet
Clinical Specifications
- Anti-Inflammatory Agents, Non-Steroidal - [CS]
- Cyclooxygenase Inhibitors - [MoA] (Mechanism of Action)
- Nonsteroidal Anti-inflammatory Drug - [EPC] (Established Pharmacologic Class)
- Serotonin 1b Receptor Agonists - [MoA] (Mechanism of Action)
- Serotonin 1d Receptor Agonists - [MoA] (Mechanism of Action)
- Serotonin-1b and Serotonin-1d Receptor Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 44183 - Currax Pharmaceuticals Llc Dba Cypress, Hawthorn, Macoven
- 44183-850 - Sumatriptan Succinate And Naproxen Sodium
- 44183-850-09 - 9 TABLET in 1 BOTTLE
- 44183-850 - Sumatriptan Succinate And Naproxen Sodium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 44183-850-09 identifies a specific commercial package of 9 tablet in 1 bottle of Sumatriptan Succinate And Naproxen Sodium, a human prescription drug labeled by Currax Pharmaceuticals Llc Dba Cypress, Hawthorn, Macoven. This tablet is formulated for oral use and contains naproxen sodium; sumatriptan succinate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Currax Pharmaceuticals Llc Dba Cypress, Hawthorn, Macoven on May 14, 2015. The current certification is valid through December 31, 2026.
How is this Currax Pharmaceuticals Llc Dba Cypress, Hawthorn, Macoven product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 44183085009. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 9 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.